Medicine and Dentistry
Neoplasm
100%
Non Small Cell Lung Cancer
68%
Biological Marker
40%
Epidermal Growth Factor Receptor
36%
Wart Virus
28%
Diagnosis
28%
Circulating Tumor DNA
25%
Methylation
25%
Cervical Cancer
24%
Next Generation Sequencing
23%
Immunohistochemistry
23%
Laryngeal Cancer
22%
Malignant Neoplasm
21%
Mouth Squamous Cell Carcinoma
19%
Radiation Therapy
19%
Diffuse Large B-Cell Lymphoma
19%
Cyclin D1
16%
Liquid Biopsy
16%
Fluorescence in Situ Hybridization
15%
Oncology
15%
Cervical Cancer Screening
15%
Neck
14%
Larynx Carcinoma
13%
Biopsy
13%
DNA Methylation
13%
Cervical Intraepithelial Neoplasia
13%
B Cell
13%
Targeted Therapy
13%
Breast Cancer
12%
Cell-Free DNA
12%
Head and Neck Squamous Cell Carcinoma
12%
Lymph Node Metastasis
12%
Circulating Tumor Cell
12%
Molecular Pathology
11%
Disease
11%
Hazard Ratio
11%
Overall Survival
11%
Mantle Cell Lymphoma
10%
Recurrent Disease
10%
Polymerase Chain Reaction
10%
Larynx Squamous Cell Carcinoma
9%
Squamous Cell Carcinoma
9%
Gastrointestinal Stromal Tumor
9%
B-Cell Lymphoma
9%
Screening
9%
Protein Expression
9%
Exon
9%
Triage
9%
Clonal Variation
8%
Drug Rapid Test
8%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
43%
Methylation
38%
B Cell
32%
Fluorescence in Situ Hybridization
24%
Next Generation Sequencing
21%
Cyclin D1
20%
Circulating Tumor DNA
19%
Wart Virus
19%
Intravenous Immunoglobulin
18%
DNA Methylation
17%
KRAS
15%
Overall Survival
13%
Decision Making
12%
Southern Blotting
12%
Exon
11%
Clonality
10%
Clonal Variation
10%
Oncogene
10%
Polymerase Chain Reaction
9%
Cortactin
9%
Heavy Chain
9%
Polymerase Chain Reaction
9%
Crizotinib
9%
Genetics
9%
Gene Amplification
9%
Progression Free Survival
8%
RNA
8%
ROS1
8%
Tumor Suppressor Gene
8%
Human Leukocyte Antigen
8%
Tissue Microarray
8%
Cancer Cell
8%
Amplicon
8%
Prevalence
7%
T Cell Receptor
7%
Immune Checkpoints
7%
Methylome
7%
Interphase
7%
Promoter Region
7%
Tyrosine Kinase Inhibitor
7%
Droplet Digital Polymerase Chain Reaction
7%
Cytogenetics
6%
Chromosomal Translocation
6%
Lymphocyte Proliferation
6%
Disease Specific Survival
5%
Epigenetics
5%
Clinical Trial
5%
Transcription Factors
5%
Carcinogenesis
5%
Laboratory Test
5%
Keyphrases
Biomarker Testing
13%
Non-small Cell Lung Cancer (NSCLC)
12%
Cyclin D1 (CCND1)
11%
High-risk Human Papillomavirus (HR-HPV)
10%
Circulating Tumor DNA (ctDNA)
10%
External Quality Assessment
9%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
9%
Molecular Diagnostics
8%
Predictive Biomarker
8%
Fluorescence in Situ Hybridization
8%
Lung Cancer
8%
Oncology
8%
Laryngeal Squamous Cell Carcinoma
7%
Radiotherapy
7%
Mantle Cell Lymphoma
7%
Local Control
7%
Fas-associated Death Domain
7%
Netherlands
7%
Laryngeal Carcinoma
6%
Lymphoma
6%
Targeted Therapy
6%
Cortactin
6%
BCL1
5%
Cervical Cancer Screening
5%
Dutch
5%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
5%
Tumor
5%
Liquid Biopsy
5%
EMS1
5%
Molecular Tumor Board
5%
Hazard Ratio
5%
Diagnostic Leukapheresis
5%
Cell-free DNA (cfDNA)
5%
